Skip to content
Screener

Integra LifeSciences IART Total Liabilities & Equity

Total Liabilities & Equity at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$50.73B-7.6%
Stryker logo
StrykerSYK
$47.93B+3.5%
Sanara MedTech Inc. logo
Sanara MedTech Inc.SMTI
$69.28M-28.1%
Axogen logo
AxogenAXGN
$304.86M+48.4%
Globus Medical logo
Globus MedicalGMED
$5.49B+10.6%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$93.42M+211%

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Operating income$19.3M+104%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Cash & equivalents$214.4M-1.6%
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.34B+35.1%
Enterprise value$3.09B+15.4%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000917520-26-000058
Line itemJune 30, 2026December 31, 2025
Preferred stock; no par value; 15,000 authorized shares; none outstanding
Common stock; $0.01 par value; 240,000 authorized shares; 92,130 and 92,286 issued at June 30, 2026 and December 31, 2025, respectively921923
Additional paid-in capital1,346,2651,338,386
Treasury stock, at cost; 14,351 shares and 14,399 shares at June 30, 2026 and December 31, 2025, respectively(686,918)(689,210)
Accumulated other comprehensive loss(40,197)(30,077)
Retained earnings423,306423,441
Total stockholders’ equity1,043,3771,043,463
Total liabilities and stockholders’ equity$3,563,490$3,602,001

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's total liabilities & equity?
Integra LifeSciences (IART) reported total liabilities & equity of $3.56B in Q2 2026.
How has Integra LifeSciences's total liabilities & equity changed year-over-year?
Integra LifeSciences's total liabilities & equity decreased by 2.8% year-over-year, from $3.67B to $3.56B.
What is the long-term trend for Integra LifeSciences's total liabilities & equity?
Over 5 years (2020 to 2025), Integra LifeSciences's total liabilities & equity has grown at a -0.1% compound annual growth rate (CAGR), from $3.62B to $3.6B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Integra LifeSciences's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude